Loading...

NovelStem International Corp.

NSTMPNK
Healthcare
Medical - Diagnostics & Research
$0.02
$0.002(11.11%)

NovelStem International Corp. (NSTM) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for NovelStem International Corp. (NSTM), covering cash flow, earnings, and balance sheets.

Revenue Growth
0.00%
Operating Income Growth
73.68%
73.68%
Net Income Growth
22.79%
22.79%
Operating Cash Flow Growth
21.91%
21.91%
Operating Margin
-7757.72%
7757.72%
Gross Margin
100.00%
100.00%
Net Profit Margin
-26942.02%
26942.02%
ROE
86.73%
86.73%
ROIC
18.10%
18.10%

NovelStem International Corp. (NSTM) Income Statement & Financial Overview

View the income breakdown for NovelStem International Corp. NSTM across both annual and quarterly reports.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$3000.00$3000.00$3000.00$3000.00
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$3000.00$3000.00$3000.00$3000.00
Gross Profit Ratio$1.00$1.00$1.00$1.00
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses-$12940.00$566551.00$144030.00$183306.00
Operating Expenses$46035.00$566551.00$144030.00$183306.00
Total Costs & Expenses$46035.00$566551.00$144030.00$183306.00
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$118675.00$105336.00$106642.00$94764.00
Depreciation & Amortization-$55975.00$0.00$0.00$180306.00
EBITDA-$1.73M-$678551.00-$141030.00$0.00
EBITDA Ratio-$575.89-$226.18-$47.01$0.00
Operating Income-$43035.00-$563551.00-$141030.00-$183310.00
Operating Income Ratio-$14.35-$187.85-$47.01-$61.10
Other Income/Expenses (Net)-$1.75M-$220336.00-$106642.00-$69764.00
Income Before Tax-$1.79M-$783887.00-$247672.00-$250070.00
Income Before Tax Ratio-$596.79-$261.30-$82.56-$83.36
Income Tax Expense$1305.00$1.68M$54953.00$53210.00
Net Income-$1.79M-$835465.00-$302625.00-$303280.00
Net Income Ratio-$597.22-$278.49-$100.88-$101.09
EPS-$0.04-$0.05-$0.006-$0.006
Diluted EPS-$0.04-$0.05-$0.006-$0.006
Weighted Avg Shares Outstanding$46.88M$46.88M$46.88M$46.88M
Weighted Avg Shares Outstanding (Diluted)$46.88M$46.88M$46.88M$46.88M

The company's financials show resilient growth, with revenue advancing from $3000.00 in Q1 2024 to $3000.00 in Q4 2024. Gross profit remained healthy with margins at 100% in Q4 2024 compared to 100% in Q1 2024. Operating income hit -$43035.00 last quarter, sustaining a consistent -1435% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$1.73M. Net income dropped to -$1.79M, while earnings per share reached -$0.04. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;